Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...


Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc.

Pfizer announces today acquisition of Bamboo Therapeutic, Inc. as a part of a growing commitment to gene therapy and rare disease, including FA. Bamboo’s portfolio includes potential best-in-class rAAV-based gene therapies in two priority areas: neuromuscular, with a pre-clinical asset for Duchenne Muscular Dystrophy (DMD); and central nervous system, with pre-clinical assets for Friedreich’s Ataxia and Canavan disease, and a Phase I asset for Giant Axonal Neuropathy.
For more information on Pfizer's interest in developing therapies for FA and rare disease visit:
Video with Pfizer Scientist Joe Nabhan, talking about his work on drug discovery for FA:

Read the Pfizer Press Release HERE

About the Author

Jen Farmer

Jen Farmer

Executive Director


FacebookTwitterLinkedinShare on Google+
Family B.jpg


Archived in
  Scientific News



Tagged in
FARA Scientific News